NL193267C - Farmaceutisch preparaat in de vorm van een gelatinecapsule met een vulling die ranitidine-hydrochloride bevat. - Google Patents
Farmaceutisch preparaat in de vorm van een gelatinecapsule met een vulling die ranitidine-hydrochloride bevat. Download PDFInfo
- Publication number
- NL193267C NL193267C NL9000428A NL9000428A NL193267C NL 193267 C NL193267 C NL 193267C NL 9000428 A NL9000428 A NL 9000428A NL 9000428 A NL9000428 A NL 9000428A NL 193267 C NL193267 C NL 193267C
- Authority
- NL
- Netherlands
- Prior art keywords
- filling
- mixture
- oily excipient
- gelatin
- ranitidine hydrochloride
- Prior art date
Links
- 239000007903 gelatin capsule Substances 0.000 title claims description 17
- 229960001520 ranitidine hydrochloride Drugs 0.000 title claims description 15
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 title claims description 15
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- 229960000620 ranitidine Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960002908 cimetidine hydrochloride Drugs 0.000 description 1
- QJHCNBWLPSXHBL-UHFFFAOYSA-N cimetidine hydrochloride Chemical compound [H+].[Cl-].N#C/N=C(/NC)NCCSCC=1N=CNC=1C QJHCNBWLPSXHBL-UHFFFAOYSA-N 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8904182 | 1989-02-23 | ||
| GB898904182A GB8904182D0 (en) | 1989-02-23 | 1989-02-23 | Pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL9000428A NL9000428A (nl) | 1990-09-17 |
| NL193267B NL193267B (nl) | 1999-01-04 |
| NL193267C true NL193267C (nl) | 1999-05-06 |
Family
ID=10652220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL9000428A NL193267C (nl) | 1989-02-23 | 1990-02-22 | Farmaceutisch preparaat in de vorm van een gelatinecapsule met een vulling die ranitidine-hydrochloride bevat. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5028432A (da) |
| JP (1) | JP2856817B2 (da) |
| KR (1) | KR940006271B1 (da) |
| AT (1) | AT401727B (da) |
| AU (1) | AU629303B2 (da) |
| BE (1) | BE1003123A3 (da) |
| CA (1) | CA2010692C (da) |
| CH (1) | CH680567A5 (da) |
| CY (1) | CY1734A (da) |
| DE (1) | DE4005650C2 (da) |
| DK (1) | DK170209B1 (da) |
| FR (1) | FR2643263B1 (da) |
| GB (2) | GB8904182D0 (da) |
| HK (1) | HK89493A (da) |
| HU (1) | HU211930A9 (da) |
| IE (1) | IE63179B1 (da) |
| IL (1) | IL93490A (da) |
| IT (1) | IT1240768B (da) |
| LU (1) | LU87681A1 (da) |
| NL (1) | NL193267C (da) |
| NZ (1) | NZ232642A (da) |
| PH (1) | PH26972A (da) |
| SA (1) | SA90100287B1 (da) |
| SE (1) | SE512412C2 (da) |
| ZA (1) | ZA901348B (da) |
| ZW (1) | ZW1790A1 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0548238A1 (en) * | 1990-09-13 | 1993-06-30 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
| US5571533A (en) * | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
| WO1994008576A1 (en) * | 1992-10-16 | 1994-04-28 | Glaxo Group Limited | Taste-masking compositions of ranitidine |
| US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| DE4341310A1 (de) * | 1993-12-03 | 1995-06-08 | Hexal Pharma Gmbh | Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1 |
| GB9325445D0 (en) | 1993-12-13 | 1994-02-16 | Cortecs Ltd | Pharmaceutical formulations |
| US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| GB9705813D0 (en) * | 1997-03-20 | 1997-05-07 | Smithkline Beecham Plc | Novel compositions |
| AR013261A1 (es) * | 1997-08-01 | 2000-12-13 | Smithkline Beecham Corp | Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina |
| WO2003055468A1 (en) * | 2001-12-21 | 2003-07-10 | Shire Laboratories Inc. | Oral capsule formulation with increased physical stability |
| WO2004069180A2 (en) * | 2003-01-31 | 2004-08-19 | Smithkline Beecham Corporation | Solid dispersion compositions |
| WO2005016312A1 (en) | 2003-08-13 | 2005-02-24 | Nobex Corporation | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| AU2010356102B2 (en) | 2010-06-23 | 2013-09-05 | Colgate-Palmolive Company | Therapeutic oral composition |
| CN103260466B (zh) | 2010-12-20 | 2016-08-17 | 高露洁-棕榄公司 | 含有亲水性活性物质、疏水性结构化剂和油载体的明胶包囊的口腔护理组合物 |
| JP2014501241A (ja) | 2010-12-20 | 2014-01-20 | コルゲート・パーモリブ・カンパニー | 歯科用閉塞活性剤、疎水性粘度調整剤および油担体を含有するゼラチンカプセル化された口腔ケア組成物 |
| SG190862A1 (en) | 2010-12-20 | 2013-07-31 | Colgate Palmolive Co | Non-aqueous oral care composition containing dental occlusion actives |
| CA3042466A1 (en) * | 2016-11-01 | 2018-05-11 | Johnson & Johnson Consumer Inc. | Liquid oral pharmaceutical dosage form |
| CN109010303B (zh) * | 2017-06-09 | 2021-05-07 | 苏州科伦药物研究有限公司 | 一种盐酸雷尼替丁胶囊的工业制备方法 |
| KR102108153B1 (ko) * | 2017-07-05 | 2020-05-07 | (주)동구바이오제약 | 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3374146A (en) * | 1966-04-18 | 1968-03-19 | American Cyanamid Co | Sustained release encapsulation |
| DE2360796B2 (de) * | 1973-12-06 | 1977-06-02 | Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm |
| GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
| IT1090703B (it) * | 1976-12-03 | 1985-06-26 | Scherer Ltd R P | Perfezionamento nelle composizioni utili quali veicolo per farmaci |
| JPS5919524B2 (ja) * | 1976-12-17 | 1984-05-07 | 中外製薬株式会社 | 安定な１α−ヒドロキシビタミンＤ類含有製剤 |
| GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
| JPS55136219A (en) * | 1979-04-11 | 1980-10-23 | Sumitomo Chem Co Ltd | Diazepam oily drug |
| EP0040489A1 (en) * | 1980-05-17 | 1981-11-25 | FISONS plc | Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine |
| IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| GB2084580B (en) * | 1980-10-01 | 1984-07-04 | Glaxo Group Ltd | Aminoalkyl furan derivative |
| EP0077529B1 (de) * | 1981-10-16 | 1985-07-17 | Sanol Schwarz GmbH | Arzneimittelformulierung |
| JPS58174308A (ja) * | 1982-04-06 | 1983-10-13 | Fujimoto Seiyaku Kk | レクタルカプセル坐剤 |
| SE8302689L (sv) * | 1982-05-14 | 1983-11-15 | Richter Gedeon Vegyeszet | Farmaceutiska kompositioner innehallande flera aktiva bestandsdelar |
| DE3237814A1 (de) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
| EP0152432B1 (en) * | 1983-08-01 | 1989-03-01 | R.P. Scherer Corporation | Sustained release method and product |
| GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| GB8426738D0 (en) * | 1984-10-23 | 1984-11-28 | Scras | Pyridine derivatives |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| JPH07549B2 (ja) * | 1986-07-03 | 1995-01-11 | ゼリア新薬工業株式会社 | 軟カプセル充填用組成物 |
| DE3629386A1 (de) * | 1986-08-29 | 1988-03-03 | Scherer Gmbh R P | Gelatinekapseln und verfahren zu ihrer herstellung |
| IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it |
| AU627775B2 (en) * | 1988-09-20 | 1992-09-03 | Glaxo Group Limited | Pharmaceutical compositions |
-
1989
- 1989-02-23 GB GB898904182A patent/GB8904182D0/en active Pending
-
1990
- 1990-02-21 ZW ZW17/90A patent/ZW1790A1/xx unknown
- 1990-02-21 LU LU87681A patent/LU87681A1/fr unknown
- 1990-02-22 US US07/482,903 patent/US5028432A/en not_active Expired - Lifetime
- 1990-02-22 IT IT47659A patent/IT1240768B/it active IP Right Grant
- 1990-02-22 IE IE65190A patent/IE63179B1/en not_active IP Right Cessation
- 1990-02-22 DK DK048090A patent/DK170209B1/da not_active IP Right Cessation
- 1990-02-22 AU AU50073/90A patent/AU629303B2/en not_active Expired
- 1990-02-22 ZA ZA901348A patent/ZA901348B/xx unknown
- 1990-02-22 NL NL9000428A patent/NL193267C/nl not_active IP Right Cessation
- 1990-02-22 SE SE9000625A patent/SE512412C2/sv unknown
- 1990-02-22 CH CH569/90A patent/CH680567A5/fr not_active IP Right Cessation
- 1990-02-22 NZ NZ232642A patent/NZ232642A/en unknown
- 1990-02-22 PH PH40086A patent/PH26972A/en unknown
- 1990-02-22 FR FR909002187A patent/FR2643263B1/fr not_active Expired - Lifetime
- 1990-02-22 AT AT0042190A patent/AT401727B/de not_active IP Right Cessation
- 1990-02-22 BE BE9000197A patent/BE1003123A3/fr not_active IP Right Cessation
- 1990-02-22 DE DE4005650A patent/DE4005650C2/de not_active Expired - Lifetime
- 1990-02-22 JP JP2042288A patent/JP2856817B2/ja not_active Expired - Lifetime
- 1990-02-22 CA CA002010692A patent/CA2010692C/en not_active Expired - Lifetime
- 1990-02-22 KR KR1019900002250A patent/KR940006271B1/ko not_active IP Right Cessation
- 1990-02-22 GB GB9004016A patent/GB2229094B/en not_active Expired - Lifetime
- 1990-02-22 IL IL9349090A patent/IL93490A/en not_active IP Right Cessation
- 1990-06-23 SA SA90100287A patent/SA90100287B1/ar unknown
-
1993
- 1993-08-26 HK HK894/93A patent/HK89493A/xx not_active IP Right Cessation
-
1994
- 1994-05-06 CY CY173494A patent/CY1734A/xx unknown
-
1995
- 1995-06-29 HU HU95P/P00543P patent/HU211930A9/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL193267C (nl) | Farmaceutisch preparaat in de vorm van een gelatinecapsule met een vulling die ranitidine-hydrochloride bevat. | |
| TWI490216B (zh) | 用作ｃ型肝炎病毒蛋白酶抑制劑之醫藥組合物 | |
| US6613353B1 (en) | Pharmaceutical formulations | |
| KR910000655B1 (ko) | 신규 형태의 연질캡슐 제조방법 | |
| CZ290314B6 (cs) | Kapalinou plněná měkká ľelatinová kapsle a způsob její výroby | |
| JPS5989618A (ja) | 無水エマルジヨンおよびその用法 | |
| CA2618705A1 (en) | Improved delivery of tetrahydrocannabinol | |
| WO1999006031A1 (en) | Pharmaceutical formulation for camptothecin analogues in gelatin capsule | |
| US6352718B1 (en) | Vasopressin antagonist formulation and process | |
| US20040146537A1 (en) | Oily wax matrix suspension formulation comprising pharmacologically active agents | |
| EP0326103B1 (en) | Pharmaceutical composition for 4-aroylimidazol-2-ones | |
| Kane et al. | A STATISTICAL MIXTURE DESIGN APPROACH FOR FORMULATING POORLY SOLUBLE COMPOUNDS IN LIQUID FILLED HARD SHELL CAPSULE | |
| EP0431659B1 (en) | Pharmaceutical compositions of tebufelone | |
| JP4139909B2 (ja) | ソフトカプセル用基剤 | |
| KR20020039354A (ko) | 바소프레신 길항제 제형 및 방법 | |
| CA2310407A1 (en) | Formulations comprising dissolved paroxetine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Effective date: 20100222 |